Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

NCT02534935 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

396

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal B Disease

Interventions

BIOLOGICAL: rLP2086 vaccine
BIOLOGICAL: Pediatric HAV vaccine

Sponsor

Pfizer